Thread: Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early PD
View Single Post
Old 10-09-2007, 11:33 AM
Stitcher's Avatar
Stitcher Stitcher is offline
Magnate
  
Join Date: Aug 2006
Posts: 2,136
15 yr Member
Stitcher Stitcher is offline
Magnate
Stitcher's Avatar
 
Join Date: Aug 2006
Posts: 2,136
15 yr Member
Frown Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early PD
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease

The Parkinson Study Group PRECEPT Investigators*

Address correspondence and reprint requests to Dr. Ira Shoulson, Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Ave, Ste 218, Rochester, NY 14620 Ira.shoulson@ctcc.rochester.edu

Background: CEP-1347 inhibits mixed lineage kinases that activate apoptotic pathways implicated in the pathogenesis of Parkinson disease (PD). CEP-1347 enhances neuronal survival in a variety of nonclinical models and was found to be safe and well tolerated during 4 weeks in PD patients. We conducted the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) to assess its disease-modifying potential in early PD.

READ FULL ARTICLE
__________________
You're alive. Do something. The directive in life, the moral imperative was so uncomplicated. It could be expressed in single words, not complete sentences. It sounded like this: Look. Listen. Choose. Act. ~~Barbara Hall

I long to accomplish a great and noble tasks, but it is my chief duty to accomplish humble tasks as though they were great and noble. The world is moved along, not only by the mighty shoves of its heroes, but also by the aggregate of the tiny pushes of each honest worker. ~~Helen Keller
Stitcher is offline   Reply With QuoteReply With Quote